5. REFERENCES

1. Chien YW. Novel drug delivery system. 2nd edition, revised and expanded, Marcel Dekker, inc., New York, 1992; p. 269-300.
2. Mathiowitz E. Encyclopedia of controlled drug delivery. Volume 2, John Wiley & Sons, Inc. 1999; p. 605-626.
3. Sultana Y, Aquil M, Ali A. Ocular insert for controlled delivery of pefloxacin mesylate: preparation and evaluation. Acta Pharma. 2005; 55: 305-314.
4. Joel G, Hardman, Lee E, Limbird, Alfred Goodman Gilman. Goodman and Gilman's the pharmacological basis of therapeutics. 10th edition, McGraw- Hill Companies, Inc. 2001, p.1179-1183.
5. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv. Ophthalmol 2004; 2: S73-S78.
6. Robertson SM, Michael AC, Barry AS, Andrew R. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans, Surv. Ophthalmol. 2005; 50: S32-S45.
7. Chrai SS, Makoid MC, Erikson SP and Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J. Pharm. Sci., 1974; 64: 333.
8. Zaki I, Fitzgerald P, Hardy JG and Wilson CG. Comparison of effect of viscosity on the precorneal residence of solution in rabbit and man. J.Pharm. Sci. 1986; 38: 463.
9. Lee VHL and Robinson JR. Mechanistic and quantitative evaluation of precorneal disposition in albino rabbits. J.Pharm. Sci. 1979; 68:673.
10. Schoenwald RD and Smolen VF. Drug absorption analysis from pharmacological data II. Transcorneal biphasic availability of Tropicamide. J.Pharm. Sci. 1971; 60 :1039.
11. Gibaldi M and Perrier D. "Pharmacokinetics, 2nd edition, Marcel Dekker, New York, 1993; p.145.
12. Pavan LD. Diagnosis and therapy of common eye infections: Bacterial, Viral and Fungal. Compr Ther. 1983; 9: 33-42.
13. Khar RK and Vyas SP. Targeted and controlled drug delivery novel carrier systems. 1st edition. CBS Publishers and Distributors, New Delhi, 2002.p. 384.
14. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Del 1995; 16:95-106.
15. Korsmeyer RW, Peppas NA. Macromolecular and modeling aspects of Swellingcontrolled systems. In: Roseman TJ, Mansdorf SZ, editors. Controlled Release

Delivery Systems. New York: Marcel Dekker, 1983; p. 77-90.
16. Darougar, Sohrab, Darougar and Dayshad, Patent literature review of ocular inserts. United States Patent 6,264,971, Appl. No. 428967, Filed on November 4, 1999.
17. Heller J. Controlled release of biologically active compounds from bioerodible polymers. Biomaterials 1980; 1:51-57.
18. Baeyens V, Kaltsatos V, Boisrame B, Varesio E. Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections. Journal of Controlled Release 1997;52: 215–220.
19. Chetonia P, Giacomo DC, Grandi M, Marco M. silicon rubber/ hydrogel composite ophthalmic inserts: preparation and preliminary *in vitro/in vivo* evaluation. European Journal of Pharmaceutics and Biopharmaceutics 1998; 46:125-132.
20. Manvi FV, Soppinath KS and Gadad AP. Development and evaluation of timolol maleate ocular inserts. Indian Drugs, 1997; 34: 264-268.
21. Narasimha Murthy S. Biodegradable polymer matrix based ocuserts of diclofenac sodium. Indian Drugs 1997; 34: 336-338.
22. Vijaya Muthu Manikandar R, Santhan Nehru Narkills R, Prabharan P. Polymeric ocular drug delivery of diclofenac sodium ophthalmic inserts. The Eastern Pharmacist 1998; 131-132.
23. Saisivam S, Muthu Manikandar RV and Nagarajan M. Design and Evaluation of ciprofloxacin hydrochloride ocuserts. Indian J. Pharma. Sci. 1999; 61: 34-38.
24. Lee YC, Millard JW, Gerald J. Salim IB. Formulation and *in vivo* evaluation of ocular insert containing phenylephrine and tropicamide. International Journal of Pharmaceutics 1999; 182: 121–126.
25. Colo GD, Burgalassi S, Chetoni P, Fiaschi M, Zambito PY. Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. International Journal of Pharmaceutics 2001; 215:101–111.
26. Karatas A, Baykara T. Studies on Indomethacin insert prepared by water soluble polymers: The relation between dissolution rate and swelling behavior. II Farmaco. 2001; 56:197-202.
27. Gerald Rajan NSM, Jayaprakash S and Somnath S. Design and Evaluation of polymeric ocular drug delivery system for controlled release of tetracycline HCL Indian J. Pharm. Sci. 2001; 12: 526-528.
28. Kawakami S, Koyo N, Takahiro M, Kenzo Y. Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert-incorporated lipophilic prodrugs. Journal of

Controlled Release 2001; 76: 255–263.

29. Dhanaraju MD, Sivakumar VR, Bhaskar K. Bioadhesive ocuserts matrix for ophthalmic administration of ciprofloxacin HCl. Indian Drugs 2002; 39: 222-4.
30. Pandit JK, Harshkumar SL. Effect of physical cross-linking on *In vitro* and *Ex vivo* permeation of indomethacin from polyvinyl alcohol ocular inserts. Indian J Pharm. Sci., 2003; 65: 146-151.
31. Dandagi PM, Manvi FV, Gadad AP and Wagh BP. Development and evaluation of ketorolac tromethamine ocular films. Indian Drugs 2003; 40: 369-71.
32. Sasaki H, Toshiaki N, Koji S, Kawakami S. One-side-coated insert as a unique ophthalmic drug delivery system. Journal of Controlled Release 2003; 92: 241– 247.
33. Margit H, Wim W, Annick L, Andreas BS. Mucoadhesive ocular insert based on thiolated poly (acrylic acid): development and *in vivo* evaluation in humans. Journal of Controlled Release 2003; 89:419–428.
34. Charoo NA, Kohli K, Ali A, Anwer A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: *In Vitro* and *In Vivo* Studies. Drug Dev Ind Pharm 2003; 29:215-221.
35. Rao V and Shyale S. Preparation and evaluation of ocular inserts containing norfloxacin. Turk J Med Sci. 2004; 34:239-246.
36. Harishkumar SL, Balasubramaniam J, Thilek Kumar M, Pandit JK. *In vitro* characterization of physically reinforced ocular inserts of indomethacin. Acta Pharmaceutica Turcica 2004; 46:17-24.
37. Mundada AS and Shrikhande BK. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug Development and Industrial Pharmacy 2006; 32: 443 – 448.
38. Sreenivas SA, Hiremanth SP and Godbole AM. Ofloxacin ocular inserts: Design formulation and evaluation. IJPT 2006; 5:159-62.
39. Sankar V, Chandrasekaran AK, Durga S, Geetha G, Ravichandran VA. Design and evaluation of diclofenac sodium ophthalmic inserts. Acta Pharmaceuticlal Sciencia 2006; 48: 5-10
40. Kamel AE, Dosari HA, Jenoobi FA. Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Delivery 2010; 13:55-59.
41. Balasubramaniam J, Srinatha A, Pandit JK, Gopalnath. In vitro microbiological evaluation of polyvinyl alcohol based ocular inserts of ciprofloxacin hydrochloride.

Indian. J. Pharm. Sci. 2009; 68:626-630.

42. Jayprakash S, Dhachinamoorthi D, Ramkanth S, Nagarajan M. Formulation and evaluation of gentamicin sulphate ocuserts. The Pharma Review 2011; 10: 131- 134.